Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

Boston Scientific Set to Acquire Bolt Medical for Up to USD 900 Million

Fineline Cube Jan 9, 2025

US major Boston Scientific Corporation (NYSE: BSX) is set to acquire Bolt Medical, Inc., a...

Company Policy / Regulatory

China’s Central Committee and State Council Outline Reforms for Elderly Care Services

Fineline Cube Jan 9, 2025

The Communist Party of China (CPC) Central Committee and State Council have released the Opinions...

Company Deals

Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery

Fineline Cube Jan 9, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary...

Policy / Regulatory

Shanghai Opens Door to Wholly Foreign-Owned Hospitals in Key Areas

Fineline Cube Jan 9, 2025

The Shanghai Municipal Health Commission, along with three other bureaus, has jointly released the “Work...

Policy / Regulatory

NHSA Strengthens Medical Security Rights for Workers in China

Fineline Cube Jan 9, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Notice on Further Strengthening the Protection...

Company Deals

Duality Biologics and Avenzo Ink Exclusive License for DB-1418/AVZO-1418

Fineline Cube Jan 8, 2025

On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced...

Company Drug

MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26

Fineline Cube Jan 8, 2025

US major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that it has received...

Company Drug

Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication

Fineline Cube Jan 8, 2025

Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...

Company Medical Device

GE Healthcare’s Allia IGS Pulse Receives NMPA Clearance for Launch in China

Fineline Cube Jan 8, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals Drug

Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Fineline Cube Jan 8, 2025

US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an...

Company Deals

Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors

Fineline Cube Jan 8, 2025

US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance...

Company Deals

Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies

Fineline Cube Jan 8, 2025

China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have...

Company Deals

PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project

Fineline Cube Jan 8, 2025

Peking University First Hospital (PKU 1st Hospital) has partnered with China-based health services and distribution...

Company Deals

Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project

Fineline Cube Jan 8, 2025

Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly...

Company Deals

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors

Fineline Cube Jan 8, 2025

LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds...

Company Deals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

Fineline Cube Jan 8, 2025

China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co.,...

Company Drug

Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease

Fineline Cube Jan 8, 2025

China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...

Company Deals

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment

Fineline Cube Jan 8, 2025

Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...

Company Drug

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction

Fineline Cube Jan 8, 2025

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...

Company Drug

Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC

Fineline Cube Jan 8, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Posts pagination

1 … 224 225 226 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.